BOSTON, Mass. — Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company advancing one-time therapies to transform the future of medicine, announced new preclinical data demonstrating proof-of-concept for its in vivo, HSC-derived CAR-M, NK, and T cell platform and its potential to durably generate lineage-restricted CAR immune cells targeting solid tumors. The findings will be presented in two poster sessions this week at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, being held November 5–9 in National Harbor, Maryland.
“While ex vivo CAR-T therapies have transformed treatment for blood cancers, use in solid tumors has been limited by multiple factors, including poor T cell infiltration and persistence in the immunosuppressive tumor microenvironment, as well as manufacturing cost and complexity,” said Jim Burns, CEO of Ensoma. “By engineering HSCs in vivo, we can develop off-the-shelf therapies that turn the body into its own cell factory—capable of continuously producing multiple CAR immune cell types that work together against solid tumors. These data move us closer to realizing this vision as we advance toward our first in vivo, HSC-derived CAR-M, NK, and T development candidate early next year.”
Ensoma’s in vivo HSC engineering platform is designed to drive durable, multi-lineage CAR immune cell generation in mice, addressing key limitations that have constrained CAR-based treatments for solid tumors. The company’s approach aims to simplify therapy manufacturing while enhancing persistence, potency, and accessibility of cell-based immunotherapies for a broader range of cancer indications.
